We are live on ! Find out more
SAM

Sectoral Asset Management Portfolio holdings

AUM $121M
1-Year Est. Return 73.47%
This Fund
S&P 500
This Quarter Est. Return
+7.77%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$800M
AUM Growth
+$24M
Cap. Flow
+$23.2M
Cap. Flow %
2.9%
Top 10 Hldgs %
39.52%
Holding
76
New
14
Increased
22
Reduced
26
Closed
9

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$25.8M
2
ABT icon
Abbott
ABT
+$21.2M
3
LLY icon
Eli Lilly
LLY
+$14M
4
CELG
Celgene Corp
CELG
+$11.6M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$9.89M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$19M
2
MRK icon
Merck
MRK
+$12.6M
3
MOH icon
Molina Healthcare
MOH
+$12.1M
4
TSRO
TESARO, Inc.
TSRO
+$11.1M
5
ABMD
Abiomed Inc
ABMD
+$8.2M

Sector Composition

Rank Sector Weight
1 Healthcare 91.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LOXO
26
DELISTED
Loxo Oncology, Inc
LOXO
$12.8M 1.6%
152,185
-93,041
-38% -$7.76M
CLVS
27
DELISTED
Clovis Oncology, Inc.
CLVS
$12.4M 1.55%
182,600
-69,099
-27% -$4.83M
NBIX icon
28
Neurocrine Biosciences
NBIX
$17.7B
$11M 1.38%
142,302
-90,300
-39% -$6.16M
IRTC icon
29
iRhythm Holdings
IRTC
$3.59B
$10.9M 1.36%
194,800
+9,600
+5% +$502K
EXAS
30
DELISTED
Exact Sciences
EXAS
$10.1M 1.26%
192,450
+74,900
+64% +$4M
VRAY
31
DELISTED
ViewRay, Inc.
VRAY
$8.77M 1.1%
+947,306
New +$7.58M
ABBV icon
32
AbbVie
ABBV
$458B
$8.25M 1.03%
+85,298
New +$8.04M
NKTR icon
33
Nektar Therapeutics
NKTR
$2.39B
$7.04M 0.88%
+7,854
New +$4.65M
MNTA
34
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$6.98M 0.87%
500,298
+127,799
+34% +$1.73M
PRTA icon
35
Prothena Corp
PRTA
$458M
$6.9M 0.86%
184,063
-11,846
-6% -$603K
WMGI
36
DELISTED
Wright Medical Group Inc
WMGI
$6.84M 0.85%
307,972
-65,700
-18% -$1.62M
PODD icon
37
Insulet
PODD
$11.3B
$6.52M 0.81%
+94,509
New +$6.2M
PTCT icon
38
PTC Therapeutics
PTCT
$6.37B
$6.22M 0.78%
372,634
+202,099
+119% +$3.42M
ALBO
39
DELISTED
Albireo Pharma Inc
ALBO
$6.22M 0.78%
242,803
+84,776
+54% +$2.15M
MASI
40
DELISTED
Masimo
MASI
$6.17M 0.77%
72,800
– –
MRK icon
41
Merck
MRK
$324B
$6.11M 0.76%
113,709
-227,184
-67% -$12.6M
EVH icon
42
Evolent Health
EVH
$475M
$6.05M 0.76%
491,982
-160,698
-25% -$2.27M
IART icon
43
Integra LifeSciences
IART
$1.54B
$5.9M 0.74%
123,198
-17,580
-12% -$860K
HRC
44
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$5.85M 0.73%
+69,450
New +$5.62M
VRTX icon
45
Vertex Pharmaceuticals
VRTX
$121B
$5.5M 0.69%
36,715
+2,715
+8% +$402K
ONCE
46
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$4.29M 0.54%
83,390
-33,209
-28% -$2.39M
ACHC icon
47
Acadia Healthcare
ACHC
$3.17B
$4.13M 0.52%
126,602
-202,908
-62% -$7.03M
MOH icon
48
Molina Healthcare
MOH
$10.3B
$4.01M 0.5%
52,260
-168,099
-76% -$12.1M
INCY icon
49
Incyte
INCY
$23.5B
$3.69M 0.46%
38,945
+5,200
+15% +$544K
MDGL icon
50
Madrigal Pharmaceuticals
MDGL
$12.6B
$3.38M 0.42%
+36,850
New +$2.1M
1
2
3 4

Similar funds

RIP
Reliant Investment Partners Pinehurst, North Carolina $121M AUM 34.77% 1-Year Est. Return
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
CF
Conquis Financial Milbrae, California $121M AUM 16.22% 1-Year Est. Return
WIM
Wiregrass Investment Management Thomasville, Georgia $121M AUM
MW
Merited Wealth North Bay Village, Florida $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM
AAA
AG Asset Advisory Los Angeles, California $121M AUM 10.78% 1-Year Est. Return
TGM
Tenzing Global Management San Francisco, California $121M AUM 85.62% 1-Year Est. Return

Sectoral Asset Management's Q4 2017 Portfolio in Review

As of Q4 2017, Sectoral Asset Management held 76 positions worth $800M, up 3.1% from $776M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Sectoral Asset Management's Q4 2017 filing shows 14 new, 22 increased, 26 reduced and 9 closed positions. Its largest new stake was Apellis Pharmaceuticals: 1,752,655 shares worth $38M. The largest sale was Gilead Sciences, an estimated $19M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 93% a quarter earlier.

  • Sectoral Asset Management's largest Q4 2017 buy was Apellis Pharmaceuticals: 1,752,655 shares worth $38M.
  • Sectoral Asset Management added most to Celgene Corp in Q4 2017, an estimated $11.6M increase.
  • Sectoral Asset Management's biggest Q4 2017 reduction was Merck, cutting an estimated $12.6M.
  • Sectoral Asset Management fully exited Gilead Sciences in Q4 2017, selling an estimated $19M.
  • Sectoral Asset Management's ten largest holdings make up 40% of its $800M portfolio in Q4 2017.
  • Sectoral Asset Management opened 14 new positions and closed 9 in Q4 2017.
  • Sectoral Asset Management's portfolio value rose 3.1% quarter-over-quarter to $800M.

Based on Sectoral Asset Management's 13F filing for Q4 2017, filed 13 Feb 2018.